The recent suspension of the PATHWAYS trial — a planned £10 million study led by King’s College London into the effects of puberty blockers on young transgender people — has become the focal point of a contentious public debate. On 12 March a legal group revealed that the Department of Health and Social Care paused preparations after receiving a letter that raised “new concerns” about the wellbeing of children and young people. Health secretary Wes Streeting publicly cited that correspondence when announcing the pause, while the department redacted parts of the document it released.
Campaigners and clinicians quickly questioned whether the pause rested solely on the single communication cited. Good Law Project has argued that the letter originated with professor Jacob George, a cardiology physician formerly attached to the study, and that his advice expressed worries about potential “long-term biological harms” and proposed increasing the minimum age to 14. That claim has intensified scrutiny of how clinical advice, personal views and policy decisions intersect in the governance of sensitive research.
Who was involved and what changed
Professor Jacob George was removed from involvement with the trial after media reporting highlighted several past online posts that expressed gender-critical positions. The reported posts included statements asserting that “gender is set at birth” and public praise for a prominent public figure known for critical views on gender identity. Following those revelations, officials described his removal as a “precautionary step.” Yet legal campaigners contend the removal reflected concerns about impartiality under rules that govern advisors to policymakers, arguing the professor’s comments could constitute a breach of those standards.
Allegations of bias and calls for clarity
Good Law Project has pressed the Health Department to confirm whether the professor’s letter was the sole impetus for the pause and whether ministers were aware of his online commentary before acting. Supporters of the study point out that puberty blockers — medically described as puberty suppressant hormones — are widely characterized in clinical literature as reversible and used internationally under clinical protocols, and say the trial’s original premise was to strengthen the evidence base. Opponents expressed safety concerns in the letter that was cited, intensifying debate over how to weigh potential risks against established clinical opinion.
Reactions from clinicians and campaigners
Clinicians and mental health professionals have criticised the decision to pause the trial as politically driven rather than evidence-led. Clinical psychologist Dr Aidan Kelly told reporters the move felt like a concession to organised opposition, not a careful prioritisation of safety. Critics note that many countries prescribe gender-affirming care and describe such treatments as safe and effective for many patients. Meanwhile, the Department of Health has said regional Children and Young People’s gender services remain available and emphasised holistic psychosocial support while the Medicines and Healthcare products Regulatory Agency and clinical leaders review the issues raised.
How similar debates are playing out abroad
The controversy in the UK echoes fraught legal developments in the United States, where courts and legislatures have been reshaping access to gender-affirming services. On 10 March a federal appeals panel upheld a state ban on Medicaid funding for gender-affirming surgery in West Virginia, marking a notable federal decision affecting adult care. The ruling described certain procedures as “experimental,” language that has alarmed advocates and clinicians who point to consensus among major medical organisations that gender-affirming care can be effective. Observers warned that judicial and political moves elsewhere may add pressure on health systems and research agendas.
Implications and next steps
The immediate consequence is an indefinite pause while regulators and clinical leads examine the concerns raised; for patients and families this creates uncertainty. Advocates continue to demand transparency about the evidence and the decision-making process, asking whether a single adviser’s concerns unduly shaped policy. Health officials insist services remain available through regional pathways and that any changes will follow formal clinical review. The episode underlines how research into trans healthcare is subject not only to scientific scrutiny but to intense public and political contestation.
As the review proceeds, stakeholders on all sides say they want clarity on what evidence will guide policies, how advisors are vetted, and how to balance robust safeguards with access to care. The pause has therefore become a wider conversation about trust in institutions, the role of expert advice, and the extent to which external political currents should influence clinical research into gender-affirming treatments.